Register Login

ENTRADA THERAPEUTICS, INC. (TRDA)

SymbolTRDA
NameENTRADA THERAPEUTICS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
AddressONE DESIGN CENTER PLACE,SUITE 17-500, BOSTON, Massachusetts, 02210, United States
Telephone+1 857 - 520-9158
Fax—
Email—
Websitehttps://www.entradatx.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001689375
Description

Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.

Additional info from NASDAQ:
Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.

2026-08-31 22:26

MPM BIOVENTURES 2018, L.P. 🔴 sold 86.9K shares of Entrada Therapeutics, Inc. (TRDA) at $7.20 Transaction Date: Aug 27, 2026 | Filing ID: 001136

Read more
2026-08-31 22:25

MPM BioVentures 2014, L.P. 🔴 sold 86.9K shares of Entrada Therapeutics, Inc. (TRDA) at $7.20 Transaction Date: Aug 27, 2026 | Filing ID: 001135

Read more
2026-08-27 01:28

MPM BioVentures 2014, L.P. 🔴 sold 62.7K shares of Entrada Therapeutics, Inc. (TRDA) at $7.54 Transaction Date: Aug 24, 2026 | Filing ID: 001107

Read more
2026-08-27 01:27

MPM BIOVENTURES 2018, L.P. 🔴 sold 62.7K shares of Entrada Therapeutics, Inc. (TRDA) at $7.54 Transaction Date: Aug 24, 2026 | Filing ID: 001106

Read more
2026-08-14 17:22

New Form SCHEDULE 13G/A - Entrada Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-352315 <b>Size:</b> 14 KB

Read more
2026-08-10 23:54

PARMAR KUSH 🔴 sold 155.3K shares of Entrada Therapeutics, Inc. (TRDA) at $7.00 ($1.1M) Transaction Date: Aug 06, 2026 | Filing ID: 000004

Read more
2026-08-10 23:52

5AM Ventures V, L.P. 🔴 sold 62.8K shares of Entrada Therapeutics, Inc. (TRDA) at $7.00 Transaction Date: Aug 06, 2026 | Filing ID: 000854

Read more
2026-08-10 20:51

New Form 144/A - Entrada Therapeutics, Inc. <b>Filed:</b> 2026-08-10 <b>AccNo:</b> 0001674324-26-000008 <b>Size:</b> 5 KB

Read more
2026-08-03 21:32

5AM Ventures V, L.P. 🔴 sold 116.5K shares of Entrada Therapeutics, Inc. (TRDA) at $6.93 Transaction Date: Jul 30, 2026 | Filing ID: 000822

Read more
2026-08-03 21:26

PARMAR KUSH 🔴 sold 116.5K shares of Entrada Therapeutics, Inc. (TRDA) at $6.93 Transaction Date: Jul 30, 2026 | Filing ID: 000002

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT07682129 Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amen… Phase2 Duchenne Muscular Dystrophy (DMD) Not_Yet_Recruiting 2026-08-01 2032-03-01 ClinicalTrials.gov
NCT07038824 A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Sk… Phase1 Duchenne Muscular Dystrophy (DMD) Recruiting 2025-08-30 2029-03-01 ClinicalTrials.gov
NCT07037862 A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Sk… Phase1 Duchenne Muscular Dystrophy (DMD) Recruiting 2025-06-30 2029-03-28 ClinicalTrials.gov
NCT04245917 Natural History Study of MNGIE — Mitochondrial Neurogastrointestinal Encephalomyopathy Suspended 2020-08-06 2026-02-01 ClinicalTrials.gov
Total clinical trials: 4
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
ENTR-601-45 - matching placebo Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-44 - matching placebo Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07037862
ENTR-601-44 Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07037862
ENTR-601-45 Other Phase PHASE2 Duchenne Muscular Dystrophy (DMD) NOT_YET_RECRUITING NCT07682129
ENTR-601-44 Other Phase PHASE2 Duchenne Muscular Dystrophy (DMD) NOT_YET_RECRUITING NCT07682129
ENTR-601-45 - matching placebo Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 - matching placebo Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 - matching placebo Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 - matching placebo Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 - matching placebo Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 - matching placebo Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 - matching placebo Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 - matching placebo Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 - matching placebo Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 - matching placebo Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 - matching placebo Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 - matching placebo Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 - matching placebo Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 - matching placebo Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
Non-interventional Other Preclinical Mitochondrial Neurogastrointestinal Encephalomyopathy SUSPENDED NCT04245917
ENTR-601-44 - matching placebo Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07037862
ENTR-601-44 Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07037862
ENTR-601-45 - matching placebo Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 Other Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 - matching placebo DRUG Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-45 DRUG Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07038824
ENTR-601-44 - matching placebo DRUG Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07037862
ENTR-601-44 DRUG Phase PHASE1 Duchenne Muscular Dystrophy (DMD) RECRUITING NCT07037862
Non-interventional OTHER Preclinical Mitochondrial Neurogastrointestinal Encephalomyopathy SUSPENDED NCT04245917
Total products: 44